Outer Biosciences trains AI on month-old living skin — SkimNews
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Outer Biosciences keeps living human skin tissue viable outside the body for up to a month — far past the industry norm of a few days — by feeding it nutrients and removing metabolic waste through a proprietary support system that preserves day-zero epidermal, stromal and immune programs.
- Michael Polansky co-founded Outer Biosciences in 2022 with Kyung-Jin Jang (chief scientist), Chris Hinojosa (CTO) and Stanley King (chief business officer), serving as CEO while also remaining executive director of Sean Parker's Parker Institute for Cancer Immunotherapy.
- The company's AI model predicts which untested chemicals will benefit specific skin functions, runs those chemicals through the living-tissue system, and feeds results back in — a loop the company says shifted output from roughly two leads in 18 months under its earlier brute-force, NCI-partnered approach to a new candidate about every six weeks, with six leads currently active.
- The universe of skin-active ingredients is tiny: only about 120 to 130 are FDA-approved across 13 OTC drug categories, and adding researched cosmetics brings the total to roughly 200 — a small pool the source explicitly calls an opportunity for new entrants.
- The OECD safety pathway lets Outer skip FDA approval since it develops cosmetic, not drug, ingredients: a single compliant study is accepted by more than 40 member countries before a partner firm commercializes the result, after the ingredient receives a standardized industry name.
- Haus Labs, Lady Gaga's cosmetics brand, collaborates with Outer at the margins — Outer's chief scientist Kyung-Jin Jang sits on Haus Labs' scientific advisory board and the two companies have run joint projects, with Germanotta herself sitting on Outer's board.
Why it matters: With only ~120-130 FDA-approved skin-active ingredients on the market, Outer Biosciences' AI-plus-living-tissue pipeline generates a new candidate roughly every six weeks — and a single OECD-compliant safety study is accepted by more than 40 countries, a market structure the source explicitly identifies as an opening for new entrants willing to invest in wet-lab-plus-AI discovery.
Ask SkimNews
